IMMUNOGENICITY OF PNEUMOCOCCAL GROUP 9 POLYSACCHARIDE-PROTEIN COMPLEX

第9组肺炎球菌是最常见的引起 肺炎球菌病 9 N和9V型多糖包含在 目前的23价肺炎球菌疫苗。 9V型病毒具有传染性 主要在幼儿中，并且在该人群中免疫原性差。 因此，我们研究了新生小鼠对9V PS的免疫应答， 多糖-蛋白质缀合物。 通过免疫印迹法将9V型PS与破伤风类毒素（TT）偶联。 PS和偶联剂的溴化氰活化， 碳二亚胺，用于缀合。 蛋白质/多糖的比例 缀合物的范围在0.23-0.41之间。 抗体的最佳剂量 9V PS的反应为2.0 mg（IgM Ab）; 1-5 mg（IgM Ab）和5.0-25 mg（IgM Ab） (IgG Ab）用于9V PS-TT缀合物。 9V型PS以及9V PS-TT结合物诱导最大IgM抗体 注射后7-9天小鼠中的应答; IgG Ab应答太低 在两组中都能检测到。 然而，当给予加强剂量时， 在初次注射后14天，高水平的IgG滴度（1.78-2.33 在给予缀合物免疫原的小鼠中诱导IgG（20 mg/ml血清）; 在给予9V PS的小鼠中未检测到Ab应答。 IgM抗体反应 在用缀合物加强注射后显示出3-4倍的增加。 相比之下，在给药组小鼠中未观察到IgM Ab应答增加。 9V PS升压注入。 PS蛋白对雌性小鼠免疫效果的研究 在交配前或妊娠期间， 新生儿9V PS正在进行中。

Group 9 pneumococci is one of the most common groups causing pneumococcal diseases. Types 9N and 9V polysaccharides are contained in the current 23-valent pneumococcal vaccine. Type 9V is infectious mainly in young children, and is poorly immunogenic in this population. Thus, we have studied the immune response of neonate mice to 9V PS using polysaccharide-protein conjugates. Type 9V PS was conjugated to tetanus toxoid (TT) by the method of cyanogen bromide activation of PS and the coupling reagent, carbodiimide, for conjugation. The ratio of protein/polysaccharide in the conjugate ranged between 0.23-0.41. The optimum doses for antibody responses were 2.0 mg (IgM Ab) for 9V PS; 1-5 mg (IgM Ab) and 5.0-25 mg (IgG Ab) for 9V PS-TT conjugate. Type 9V PS as well as 9V PS-TT conjugate induced maximum IgM antibody response in mice 7-9 days after injection; IgG Ab response was too low to be detected in both groups. However, when the booster dose was given at 14 days after primary injection, a high level of IgG titer (1.78-2.33 mg/ml serum) was induced in mice given the conjugate immunogen; the IgG Ab response was not detectable in mice given 9V PS. The IgM Ab response showed 3-4 fold increase after the booster injection with the conjugate. In contrast, no increase in IgM Ab response was observed in mice given 9V PS booster injection. Studies on effects of the immunization of female mice with PS-protein conjugate before mating or during pregnancy on the antibody responses of neonates to 9V PS are in progress.